Pharmacogenetics driving personalized medicine: analysis of genetic polymorphisms related to breast cancer medications in Italian isolated populations

Table 3 At risk genotype’s counts by drug/therapy class

Class number	Drug class	At risk genotype	At risk genotype count	Samples	Genotype frequency
1	Fluoropyrimidines
	rs2297595 + rs1048943 + rs3918290	CC + CT & TT & TT + CT	0	1581	0
	rs2297595 + rs1048943	CC + CT & TT	20	1581	1.26 %
	rs2297595 + rs3918290	CC + CT & TT + CT	1	1581	0.06 %
	rs1048943 + rs3918290	TT & TT + CT	1	1581	0.06 %
2	Alkylating agents
2	rs4880 + rs4244285	GA + GG & AA	4	331	1.20 %
3	Monoclonal antibodies
3	rs1136201 + rs1801274	GA & GG + GA	291	1581	18.40 %

Out of six classes, members of three of them (i.e., the breast cancer medications) did not share any of the reported at risk genotype. For class 1, three SNPs related with Fluoropyrimidines were found and different combinations are reported. Drug class class of drugs or treatment, At risk genotype risk genotype for the class, At risk genotype count count of joint risk genotypes for the class, Samples total number of analyzed samples, Genotype frequency at risk genotype frequency

ISSN: 1479-5876